Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design

Lancet Infectious Diseases

Volumn 6, Issue 8, 2006, Pages 522-528

  Ibanga, Hannah B ^a   Brookes, Roger H ^a   Hill, Philip C ^a   Owiafe, Patrick K ^a   Fletcher, Helen A ^c   Lienhardt, Christian ^b   Hill, Adrian VS ^c   Adegbola, Richard A ^a   McShane, Helen ^c  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Senegal)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DNA VACCINE; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; MVA 85A; MYCOBACTERIUM ANTIGEN; MYCOBACTERIUM ANTIGEN 85A; MYCOBACTERIUM ANTIGEN 85B; MYCOBACTERIUM ANTIGEN CFP10; MYCOBACTERIUM ANTIGEN ESAT6; MYCOBACTERIUM VACCINE; RECOMBINANT VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFORMED CONSENT; LUNG DISEASE; MEDICAL ETHICS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; SPINE DISEASE; T LYMPHOCYTE; TISSUE NECROSIS; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; VACCINIA VIRUS; VIRUS RECOMBINANT;

ACYLTRANSFERASES; AFRICA; ANTIGENS, BACTERIAL; CLINICAL TRIALS; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNOCOMPROMISED HOST; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, SUBUNIT; VACCINIA VIRUS;

EID: 33746740120     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(06)70552-7     Document Type: Review

References (46)

1. WHO. TB, a global emergency (1994), WHO, Geneva
2. WHO Regional Office for Africa. TB emergency declaration. http://www.who.int/tb/features_archive/tb_emergency_declaration/en/print .html (accessed July 3, 2006)
3. Dye C., Scheele S., Dolin, P Pathania V., and Raviglione M. Global burden of tuberculosis. JAMA 282 (1999) 677-689
4. Fine P., Carneiro I., Milstien J., and Clements C. Issues relating to the use of BCG in immunisation programmes (1999), WHO, Geneva
5. Rodrigues L., Diwan V., and Wheeler J. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 22 (1993) 1154-1158
6. Fine P. The BCG story: lessons from the past and implications for the future. Rev Infect Dis 11 suppl 2 (1989) S353-S359
7. Rodrigues L., Pereira S., Cunha S., et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 366 (2005) 1290-1295
8. Black G., Weir R., Floyd S., et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 359 (2002) 1393-1401
9. Brandt L., Feino Cunha J., Weinreich Olsen A., et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 70 (2002) 672-678
10. Behr M. BCG-different strains, different vaccines?. Lancet Infect Dis 2 (2002) 86-92
11. Comstock G., and Palmer C. Long term results of BCG vaccination in the southern United States. Am Rev Respir Dis 94 (1966) 553-568
12. Epstein P. BCG vaccination and nutrition. Lancet 335 (1990) 1536-1537
13. Flynn J., and Chan J. Immunology of tuberculosis. Annu Rev Immunol 19 (2001) 93-129
14. Kaufmann S. How can immunology contribute to the control of tuberculosis?. Nat Rev Immunol 1 (2001) 20-30
15. Ellner J., Hirsch C., and Whalen C. Correlates of protective immunity to Mycobacterium tuberculosis in humans. Clin Infect Dis 30 suppl 3 (2000) S279-S282
16. McShane H., Pathan A., Sander C., Goonetilleke N., Fletcher H., and Hill A. Boosting BCG with MVA85A, the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 85 (2005) 47-52
17. McShane H., Pathan A., Sander C., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG primed and naturally acquired anti-mycobacterial immunity in humans. Nat Med 10 (2004) 1240-1244
18. Horwitz M., Harth G., Dillon B., and Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 97 (2000) 13853-13858
19. Horwitz M. Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. Microbes Infect 7 (2005) 947-954
20. Skeiky Y., Alderson M., Ovendale P., et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172 (2004) 7618-7628
21. National Institute of Allergy and Infectious Diseases. Preventing TB. Closing in: the long road to a TB vaccine. http://www3.niaid.nih.gov/news/focuson/tb/research/preventing/ prevention_road.htm (accessed June 9, 2006)
22. Skeiky Y., and Sadoff J. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4 (2006) 469-476
23. von Reyn C. Tuberculosis vaccine trials. Lancet Infect Dis 5 (2005) 132
24. Rook G., and Attiyah A. Cytokines and the Koch phenomenon. Tubercle 72 (1991) 13-20
25. Koch R. Fortstzung über ein Heilmittel gegen Tuberculose. Dtsch Med Wochenschr 17 (1891) 101-102
26. Taylor J., Turner O., Basaraba R., Belisle J., Huygen K., and Orme I. Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect Immun 71 (2003) 2192-2198
27. Vekemans J., Ota M., Sillah J., et al. Immune responses to mycobacterial antigens in the Gambian population: implications for vaccines and immunodiagnostic test design. Infect Immun 72 (2004) 381-388
28. Hill P., Fox A., Jeffries D., et al. Quantitative T cell assay reflects infectious load of Mycobacterium tuberculosis in an endemic case contact model. Clin Infect Dis 40 (2005) 273-278
29. Lee E., and Holzman R. Evolution and current use of the tuberculin test. Clin Infect Dis 34 (2002) 365-370
30. Horowitz H., Luciano B., Kadel J., and Wormser G. Tuberculin skin test conversion in hospital employees vaccinated with bacille Calmette-Guerin: recent Mycobacterium tuberculosis infection or booster effect?. Am J Infect Control 23 (1995) 181-217
31. Edwards L., and Palmer C. Epidemiologic studies of tuberculin sensitivity, I: preliminary results with purified protein derivatives prepared from atypical acid fast organism. Am J Hyg 66 (1958) 213-221
32. Markowitz N., Hansen N., Wilcosky T., et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Pulmonary Complications of HIV Infection Study Group. Ann Intern Med 119 (1993) 185-193
33. Lienhardt C., Fielding K., Sillah J., et al. Risk factors for tuberculosis infection in sub-Saharan Africa: a contact study in The Gambia. Am J Respir Crit Care Med 168 (2003) 448-455
34. Pai M., Riley L., and Colford Jr. J. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 4 (2004) 761-776
35. Barnes P. Diagnosing latent tuberculosis infection: turning glitter to gold. Am J Respir Crit Care Med 170 (2004) 5-6
36. Sorensen A., Nagai S., Houen G., Andersen P., and Andersen A. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun 63 (1995) 1710-1717
37. Harboe M., Oettinger T., Wiker H., Rosenkrands I., and Andersen P. Evidence for occurence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun 64 (1996) 16-22
38. Pollock J., and Andersen P. The potential of the ESAT-6 antigen secreted by virulent mycobacteria for specific diagnosis of tuberculosis. J Infect Dis 175 (1997) 1251-1254
39. Lalvani A., Brookes R., Hambleton S., Britton W., Hill A., and McMichael A. Rapid effector function in CD8+ memory T cells. J Exp Med 186 (1997) 859-865
40. Hill P., Brookes R., Fox A., et al. Large-scale evaluation enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis 38 (2004) 966-973
41. Grindulis H., Baynham M., Scott P., Thompson R., and Wharton B. Tuberculin response two years after BCG vaccination at birth. Arch Dis Child 59 (1984) 614-619
42. Floyd S., Ponnighaus J., Bliss L., et al. BCG scars in northern Malawi: sensitivity and repeatability of scar reading, and factors affecting size. Int J Tuberc Lung Dis 4 (2000) 1133-1142
43. Schim van der Loeff M., Sarge-Njie R., Ceesay S., et al. Regional differences in HIV trends in The Gambia: results from sentinel surveillance among pregnant women. AIDS 17 (2003) 1841-1846
44. Godfrey-Faussett P., Baggaley R., Mwinga A., et al. Recruitment to a trial of tuberculosis preventive therapy from a voluntary HIV testing centre in Lusaka: relevance to implementation. Trans R Soc Trop Med Hyg 89 (1995) 354-358
45. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont report. OPRR Reports (1988), US Government Printing Office, Washington, DC Report numberGPO 887-809
46. Emanuel E., Currie X., and Herman A. Undue inducement in clinical research in developing countries: is it a worry?. Lancet 366 (2005) 336-340